SCHEMBL718705

SCHEMBL718705

COCc1c(C(Nc2ccc(C(=O)OC)cc2)C2CCCCC2)oc2ccc(F)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.41
RAB9A P51151 5/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
CTSL P07711 1/20 0.40
CTSS P25774 1/20 0.40
KMT2A Q03164 5/20 0.39
MEN1 O00255 4/20 0.39
HTT P42858 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
EPHX2 P34913 2/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ATM Q13315 1/20 0.37
TEAD4 Q15561 1/20 0.36
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719816 0.93 NPC1 (0.41) NPC1RAB9AALDH1A1LMNACTSL
SCHEMBL719559 0.92 NPC1 (0.40) NPC1RAB9AALDH1A1LMNACTSL
SCHEMBL14905708 0.87 NPC1 (0.48) NPC1RAB9AALDH1A1LMNACTSL
SCHEMBL10284568 0.87 NAMPT (0.37) NPC1RAB9AALDH1A1CTSLCTSS
SCHEMBL718473 0.87 GCG (0.44) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL721576 0.86 NAMPT (0.37) NPC1RAB9AALDH1A1CTSLCTSS
SCHEMBL718743 0.85 NPC1 (0.40) NPC1RAB9AALDH1A1CTSLCTSS
SCHEMBL717820 0.84 MEN1 (0.46) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL719320 0.83 NPC1 (0.35) NPC1RAB9AALDH1A1CTSLCTSS
SCHEMBL720138 0.81 NPC1 (0.34) NPC1RAB9AALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.